Catalent to Acquire RheinCell Therapeutics
Catalent expands capabilities for stem cell-based therapies with acquisition of RheinCell’s GMP-grade human iPSCs.
Catalent announced on June 24, 2021 an agreement to acquire RheinCell Therapeutics GmbH, a Langenfeld, Germany-based developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs), further expanding its custom cell therapy process development and manufacturing capabilities.
In making the announcement, Catalent reported that the acquisition will allow it to offer the building blocks to scale iPSC-based cell therapies and reduce barriers to entry to the clinic for therapeutic companies.
iPSC cell types can address a number of therapeutic indications. RheinCell has researched and developed full GMP human leukocyte antigen-matched cell banks.
Upon closing, which is expected before the end of 2021, RheinCell’s current employees will join Catalent’s Cell & Gene Therapy business.
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
